drugset / Trial / NCT04387071
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Phase 1/2
Terminated
2 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in a protein, known as a virus-like particle (VLP). VLPs are detected and processed by cells of the immune system. The DNA contained in CMP-001 activates the immune system and recruit cells of the immune system to the tumor. INCAGN01949 is an antibody, a type of protein, which has been shown to stimulate the immune system. Injecting CMP-001 and INCAGN01949 directly into the tumor may work against tumor cells to slow tumor growth by causing tumor cells to die.
Timeline
- Start
- 2021-04-29
- Primary completion
- 2022-12-28
- Completion
- 2022-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCAGN01949 | Monoclonal antibody | 250 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 500 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 1000 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 1670 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 2505 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 3507 ug/m2 | Other |
| Subject | INCAGN01949 | Monoclonal antibody | 4559 ug/m2 | Other |
| Subject | Vidutolimod | Other / unclassified | 10 mg | Subcutaneous |